Thompson Investment Management Inc. Sells 916 Shares of GSK PLC Sponsored ADR $GSK

Thompson Investment Management Inc. trimmed its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 39.2% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 1,420 shares of the pharmaceutical company’s stock after selling 916 shares during the quarter. Thompson Investment Management Inc.’s holdings in GSK were worth $55,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the business. Kingsview Wealth Management LLC grew its position in GSK by 1.8% during the first quarter. Kingsview Wealth Management LLC now owns 15,227 shares of the pharmaceutical company’s stock valued at $590,000 after buying an additional 271 shares during the period. Rehmann Capital Advisory Group boosted its position in shares of GSK by 4.6% in the first quarter. Rehmann Capital Advisory Group now owns 6,407 shares of the pharmaceutical company’s stock worth $248,000 after purchasing an additional 279 shares during the period. First PREMIER Bank boosted its position in shares of GSK by 6.5% in the first quarter. First PREMIER Bank now owns 4,659 shares of the pharmaceutical company’s stock worth $181,000 after purchasing an additional 286 shares during the period. OneAscent Financial Services LLC boosted its position in shares of GSK by 3.9% in the first quarter. OneAscent Financial Services LLC now owns 7,700 shares of the pharmaceutical company’s stock worth $297,000 after purchasing an additional 292 shares during the period. Finally, Rhumbline Advisers boosted its position in shares of GSK by 2.1% in the first quarter. Rhumbline Advisers now owns 18,403 shares of the pharmaceutical company’s stock worth $713,000 after purchasing an additional 386 shares during the period. 15.74% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have weighed in on GSK. Weiss Ratings reiterated a “hold (c)” rating on shares of GSK in a research report on Wednesday. Wall Street Zen upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 5th. Seven analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, GSK has a consensus rating of “Reduce” and an average target price of $37.38.

GSK Price Performance

GSK stock opened at $43.53 on Friday. GSK PLC Sponsored ADR has a one year low of $31.72 and a one year high of $45.59. The company’s fifty day moving average price is $40.33 and its 200-day moving average price is $38.85. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87. The company has a market capitalization of $88.55 billion, a PE ratio of 20.15, a price-to-earnings-growth ratio of 1.96 and a beta of 0.53.

GSK (NYSE:GSK) last released its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, topping the consensus estimate of $1.12 by $0.11. GSK had a net margin of 10.81% and a return on equity of 49.22%. The firm had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $7.92 billion. During the same quarter in the previous year, the firm earned $0.43 earnings per share. The company’s quarterly revenue was up 1.3% compared to the same quarter last year. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. On average, equities analysts anticipate that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.

GSK Cuts Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, October 9th. Stockholders of record on Friday, August 15th were issued a $0.4206 dividend. This represents a $1.68 annualized dividend and a dividend yield of 3.9%. The ex-dividend date of this dividend was Friday, August 15th. GSK’s payout ratio is 78.24%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.